Valuation: AbbVie Inc.

Market Cap 518B 470B 434B 392B 739B 48,359B 768B 5,230B 2,069B 26,095B 1,942B 1,901B 82,448B P/E 2026 *
37.3x
P/E 2027 * 27.5x
Enterprise Value 581B 527B 487B 439B 830B 54,267B 861B 5,869B 2,321B 29,283B 2,179B 2,133B 92,519B EV / Sales 2026 *
8.57x
EV / Sales 2027 * 7.73x
Free-Float
95.51%
Yield 2026 *
2.36%
Yield 2027 * 2.48%
1 day+0.74%
1 week-0.36%
Current month-0.70%
1 month+2.59%
3 months+16.97%
6 months+39.18%
Current year+28.15%
1 week 291
Extreme 291
301.2
1 month 278.01
Extreme 278.01
302.93
Current year 190.75
Extreme 190.75
302.93
1 year 190.75
Extreme 190.75
302.93
3 years 137.14
Extreme 137.14
302.93
5 years 115.01
Extreme 115.01
302.93
10 years 58.6
Extreme 58.6
302.93
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Free

Director

59 0.0000%
9/30/26 A Free

Director

129 0.0000%
8/14/26 A Exercice

Executive/Senior Manager

98,130 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%-0.36%+25.14%+111.73% 518B
-1.13%-1.17%+38.55%+139.23% 1,261B
-1.36%-0.74%+39.64%+86.06% 671B
+0.06%+1.02%+32.38%+71.20% 387B
-0.75%-3.16%+54.39%+40.90% 353B
-0.43%-0.11%+30.00%+57.33% 300B
-0.62%-1.47%+0.93%+35.48% 283B
-0.95%-1.57%+34.01%+72.55% 248B
+1.60%-0.36%+37.21%+125.66% 211B
-0.25%+0.64%-9.97%-60.97% 179B
Average -0.40%+0.13%+28.23%+67.92% 441B
Weighted average by Cap. -0.42%-0.34%+32.59%+89.32%

Financials

2026 *2027 *
Net sales 67.79B 61.54B 56.85B 51.29B 96.82B 6,334B 101B 685B 271B 3,418B 254B 249B 10,799B 74.02B 67.2B 62.07B 56B 106B 6,916B 110B 748B 296B 3,732B 278B 272B 11,791B
Net income 14.35B 13.03B 12.03B 10.86B 20.5B 1,341B 21.28B 145B 57.36B 724B 53.84B 52.71B 2,286B 19.32B 17.54B 16.2B 14.61B 27.59B 1,805B 28.65B 195B 77.21B 974B 72.48B 70.95B 3,077B
Net Debt 63.23B 57.4B 53.02B 47.83B 90.3B 5,907B 93.76B 639B 253B 3,188B 237B 232B 10,071B 54.29B 49.28B 45.53B 41.07B 77.53B 5,072B 80.5B 549B 217B 2,737B 204B 199B 8,648B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
17/11/26 $292.82 -0.59% 3,950,014
16/11/26 $294.55 -0.16% 5,493,798
13/11/26 $295.03 +0.20% 3,262,103
12/11/26 $294.45 -0.18% 4,826,816
11/11/26 $294.98 +0.37% 3,262,250
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
292.82USD
Average target price
315.88USD
Spread / Average Target
+7.88%
  1. Stock Market
  2. Stocks
  3. ABBV Stock